×
S&P 500   4,126.48 (+1.69%)
DOW   32,960.75 (+0.99%)
QQQ   306.73 (+2.47%)
AAPL   148.33 (+3.16%)
MSFT   271.02 (+1.93%)
FB   193.88 (+1.17%)
GOOGL   2,234.95 (+3.67%)
AMZN   2,259.46 (+1.71%)
TSLA   751.19 (+6.14%)
NVDA   186.03 (+4.21%)
BABA   92.99 (-1.58%)
NIO   16.33 (+1.87%)
AMD   100.65 (+1.92%)
CGC   4.90 (-11.71%)
MU   72.68 (+2.95%)
T   21.24 (-0.38%)
GE   77.69 (+0.88%)
F   13.50 (+2.90%)
DIS   108.17 (+2.42%)
AMC   13.46 (+10.06%)
PFE   53.59 (-0.74%)
PYPL   85.00 (+5.70%)
NFLX   194.64 (+1.69%)
S&P 500   4,126.48 (+1.69%)
DOW   32,960.75 (+0.99%)
QQQ   306.73 (+2.47%)
AAPL   148.33 (+3.16%)
MSFT   271.02 (+1.93%)
FB   193.88 (+1.17%)
GOOGL   2,234.95 (+3.67%)
AMZN   2,259.46 (+1.71%)
TSLA   751.19 (+6.14%)
NVDA   186.03 (+4.21%)
BABA   92.99 (-1.58%)
NIO   16.33 (+1.87%)
AMD   100.65 (+1.92%)
CGC   4.90 (-11.71%)
MU   72.68 (+2.95%)
T   21.24 (-0.38%)
GE   77.69 (+0.88%)
F   13.50 (+2.90%)
DIS   108.17 (+2.42%)
AMC   13.46 (+10.06%)
PFE   53.59 (-0.74%)
PYPL   85.00 (+5.70%)
NFLX   194.64 (+1.69%)
S&P 500   4,126.48 (+1.69%)
DOW   32,960.75 (+0.99%)
QQQ   306.73 (+2.47%)
AAPL   148.33 (+3.16%)
MSFT   271.02 (+1.93%)
FB   193.88 (+1.17%)
GOOGL   2,234.95 (+3.67%)
AMZN   2,259.46 (+1.71%)
TSLA   751.19 (+6.14%)
NVDA   186.03 (+4.21%)
BABA   92.99 (-1.58%)
NIO   16.33 (+1.87%)
AMD   100.65 (+1.92%)
CGC   4.90 (-11.71%)
MU   72.68 (+2.95%)
T   21.24 (-0.38%)
GE   77.69 (+0.88%)
F   13.50 (+2.90%)
DIS   108.17 (+2.42%)
AMC   13.46 (+10.06%)
PFE   53.59 (-0.74%)
PYPL   85.00 (+5.70%)
NFLX   194.64 (+1.69%)
S&P 500   4,126.48 (+1.69%)
DOW   32,960.75 (+0.99%)
QQQ   306.73 (+2.47%)
AAPL   148.33 (+3.16%)
MSFT   271.02 (+1.93%)
FB   193.88 (+1.17%)
GOOGL   2,234.95 (+3.67%)
AMZN   2,259.46 (+1.71%)
TSLA   751.19 (+6.14%)
NVDA   186.03 (+4.21%)
BABA   92.99 (-1.58%)
NIO   16.33 (+1.87%)
AMD   100.65 (+1.92%)
CGC   4.90 (-11.71%)
MU   72.68 (+2.95%)
T   21.24 (-0.38%)
GE   77.69 (+0.88%)
F   13.50 (+2.90%)
DIS   108.17 (+2.42%)
AMC   13.46 (+10.06%)
PFE   53.59 (-0.74%)
PYPL   85.00 (+5.70%)
NFLX   194.64 (+1.69%)
NASDAQ:ATRS

Antares Pharma (ATRS) Stock Forecast, Price & News

$5.59
0.00 (0.00%)
(As of 05/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.59
$5.59
50-Day Range
$3.74
$5.59
52-Week Range
$3.11
$5.60
Volume
237 shs
Average Volume
3.29 million shs
Market Capitalization
$955.06 million
P/E Ratio
23.29
Dividend Yield
N/A
Beta
1.15
30 days | 90 days | 365 days | Advanced Chart
Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter.

Antares Pharma logo

About Antares Pharma

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ATRS
CUSIP
03664210
Employees
201
Year Founded
N/A

Sales & Book Value

Annual Sales
$183.98 million
Cash Flow
$0.13 per share
Book Value
$1.03 per share

Profitability

Net Income
$46.29 million
Pretax Margin
29.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
160,772,000
Market Cap
$955.06 million
Optionable
Optionable

Company Calendar

Last Earnings
3/03/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

719th out of 1,424 stocks

Surgical & Medical Instruments Industry

78th out of 137 stocks

Analyst Opinion: 2.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -













Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

Is Antares Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Antares Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRS, but not buy additional shares or sell existing shares.
View analyst ratings for Antares Pharma
or view top-rated stocks.

Are investors shorting Antares Pharma?

Antares Pharma saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 4,780,000 shares, a decline of 34.3% from the April 30th total of 7,280,000 shares. Based on an average daily trading volume, of 4,620,000 shares, the short-interest ratio is presently 1.0 days. Approximately 2.9% of the shares of the stock are sold short.
View Antares Pharma's Short Interest
.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Antares Pharma
.

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) announced its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $41.56 million during the quarter, compared to the consensus estimate of $44.01 million. Antares Pharma had a trailing twelve-month return on equity of 7.43% and a net margin of 21.90%.
View Antares Pharma's earnings history
.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma updated its FY 2022 earnings guidance on Thursday, March, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200 million-$220 million, compared to the consensus revenue estimate of $211.41 million.

What price target have analysts set for ATRS?

5 brokers have issued 1 year price targets for Antares Pharma's shares. Their forecasts range from $5.60 to $5.60. On average, they expect Antares Pharma's stock price to reach $5.60 in the next year. This suggests a possible upside of 0.2% from the stock's current price.
View analysts' price targets for Antares Pharma
or view top-rated stocks among Wall Street analysts.

Who are Antares Pharma's key executives?
Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 56, Pay $1M)
  • Mr. Fred M. Powell CPA, Exec. VP & CFO (Age 61, Pay $636.39k)
  • Mr. Peter J. Graham Esq., Exec. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 55, Pay $634.48k)
  • Mr. Patrick Madsen, Sr. VP of Operations
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 59)
  • Ms. Tram Bui, VP of Corp. Communications & Investor Relations
  • Mr. Edward Tykot, Sr. VP of Corp. Bus. Devel.
  • Mr. Claude E. Richardson, Sr. VP of HR
  • Dr. Peter Sadowski, Sr. VP of Technology Portfolio & Intellectual Property (Age 74)
  • Dr. Jonathan S. Jaffe, Interim EVP, Pharmaceutical R&D and Chief Medical Officer
What is Paul K. Wotton's approval rating as Antares Pharma's CEO?

5 employees have rated Antares Pharma CEO Paul K. Wotton on Glassdoor.com. Paul K. Wotton has an approval rating of 18% among Antares Pharma's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.00%), Vanguard Group Inc. (5.06%), State Street Corp (2.02%), Russell Investments Group Ltd. (1.78%), First Wilshire Securities Management Inc. (1.64%) and Dimensional Fund Advisors LP (1.13%). Company insiders that own Antares Pharma stock include Anton Gueth, Fred M Powell, Leonard S Jacob, Peter J Graham, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma
.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, State Board of Administration of Florida Retirement System, Victory Capital Management Inc., BlackRock Inc., Northern Trust Corp, SG Americas Securities LLC, JPMorgan Chase & Co., and Invesco Ltd..
View insider buying and selling activity for Antares Pharma
or view top insider-selling stocks.

Which major investors are buying Antares Pharma stock?

ATRS stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Velan Capital Investment Management LP, Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Boston Partners, Renaissance Technologies LLC, Vanguard Group Inc., and State Street Corp.
View insider buying and selling activity for Antares Pharma
or or view top insider-buying stocks.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $5.59.

How much money does Antares Pharma make?

Antares Pharma has a market capitalization of $955.06 million and generates $183.98 million in revenue each year. The specialty pharmaceutical company earns $46.29 million in net income (profit) each year or $0.239990 on an earnings per share basis.

How many employees does Antares Pharma have?

Antares Pharma employs 201 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at (609) 359-3020, via email at [email protected], or via fax at 302-655-5049.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.